Clinical management of liver cancer patients with immune checkpoint inhibitors treatment.

IF 1.3 Q4 ONCOLOGY

Hepatic Oncology Pub Date : 2025-12-01 Epub Date: 2025-10-30 DOI:10.1080/20450923.2025.2578079

Johnny C W Yau, Landon L Chan, Stephen L Chan

{"title":"Clinical management of liver cancer patients with immune checkpoint inhibitors treatment.","authors":"Johnny C W Yau, Landon L Chan, Stephen L Chan","doi":"10.1080/20450923.2025.2578079","DOIUrl":null,"url":null,"abstract":"<p><p>The treatment paradigm of hepatocellular carcinoma (HCC) has evolved with the emergence of immune checkpoint inhibitors (ICIs). Two ICI-based regimens have gained regulatory approval worldwide in unresectable HCC as first line treatment based on the IMBrave150 and HIMALAYA trial. Other regimens such as camrelizumab-rivoceranib and ipilimumab-nivolumab also demonstrated improvement in overall survival as compared to multi-targeted agents in recent phase III clinical trials. With the growing amount of evidence, it is imperative for clinicians to decide the most suitable ICI therapy for each patient based on their disease status and tolerability. Furthermore, ICI in combination with locoregional treatment such as transarterial chemoembolization (TACE) has been shown to prolong the progression-free survival as compared to TACE alone. In early-stage HCC, the role of ICI has been studied in both the adjuvant and neoadjuvant setting. In this narrative review, we will highlight the major advancement of ICI in different stages of HCC and their implication in real world practice. The unmet need in the special population of liver cancer patients and the management of immune-related hepatitis will also be addressed.</p>","PeriodicalId":44854,"journal":{"name":"Hepatic Oncology","volume":"12 1","pages":"2578079"},"PeriodicalIF":1.3000,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12578309/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hepatic Oncology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/20450923.2025.2578079","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/10/30 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

The treatment paradigm of hepatocellular carcinoma (HCC) has evolved with the emergence of immune checkpoint inhibitors (ICIs). Two ICI-based regimens have gained regulatory approval worldwide in unresectable HCC as first line treatment based on the IMBrave150 and HIMALAYA trial. Other regimens such as camrelizumab-rivoceranib and ipilimumab-nivolumab also demonstrated improvement in overall survival as compared to multi-targeted agents in recent phase III clinical trials. With the growing amount of evidence, it is imperative for clinicians to decide the most suitable ICI therapy for each patient based on their disease status and tolerability. Furthermore, ICI in combination with locoregional treatment such as transarterial chemoembolization (TACE) has been shown to prolong the progression-free survival as compared to TACE alone. In early-stage HCC, the role of ICI has been studied in both the adjuvant and neoadjuvant setting. In this narrative review, we will highlight the major advancement of ICI in different stages of HCC and their implication in real world practice. The unmet need in the special population of liver cancer patients and the management of immune-related hepatitis will also be addressed.

Abstract Image

查看原文本刊更多论文

免疫检查点抑制剂治疗肝癌患者的临床管理。

随着免疫检查点抑制剂（ICIs）的出现，肝细胞癌（HCC）的治疗模式发生了变化。基于IMBrave150和HIMALAYA试验，两种基于ci的方案已在全球范围内获得监管机构批准，作为不可切除HCC的一线治疗。在最近的III期临床试验中，与多靶向药物相比，camrelizumab- rivoeranib和ipilimumab-nivolumab等其他方案也显示出总体生存期的改善。随着越来越多的证据，临床医生必须根据每个患者的疾病状况和耐受性来决定最适合的ICI治疗。此外，与单独使用TACE相比，ICI联合局部治疗如经动脉化疗栓塞（TACE）可延长无进展生存期。在早期HCC中，ICI在辅助治疗和新辅助治疗中的作用已经被研究过。在这篇叙述性综述中，我们将重点介绍HCC不同阶段ICI的主要进展及其在现实世界实践中的意义。肝癌患者特殊人群的未满足需求和免疫相关肝炎的管理也将得到解决。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Hepatic Oncology ONCOLOGY-

CiteScore

0.40

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Primary liver cancer is the sixth most common cancer in the world, and the third most common cause of death from malignant disease. Traditionally more common in developing countries, hepatocellular carcinoma is becoming increasingly prevalent in the Western world, primarily due to an increase in hepatitis C virus infection. Emerging risk factors, such as non-alcoholic fatty liver disease and obesity are also of concern for the future. In addition, metastatic tumors of the liver are more common than primary disease. Some studies report hepatic metastases in as many as 40 to 50% of adult patients with extrahepatic primary tumors. Hepatic Oncology publishes original research studies and reviews addressing preventive, diagnostic and therapeutic approaches to all types of cancer of the liver, in both the adult and pediatric populations. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Hepatic Oncology provides a forum to report and debate all aspects of cancer of the liver and bile ducts. The journal publishes original research studies, full reviews and commentaries, with all articles subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal''s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3.